For the first time in a decade, opioid overdose deaths in the United States declined year-over-year, falling 12% from the previous year's record high of 81,083 deaths. The reduction represents approximately 9,700 lives saved compared to the prior year and is being attributed to a combination of expanded naloxone access, harm reduction programs, and β in some regions β declining fentanyl supply due to law enforcement disruption of trafficking networks.
The single most impactful factor appears to be naloxone. Since the FDA approved over-the-counter sales of Narcan nasal spray in 2023, the drug has become available in every CVS, Walgreens, and Rite Aid in America without a prescription. Health departments in 45 states now distribute naloxone for free at pharmacies, community organizations, and through mail-order programs. It is estimated that naloxone reversed over 1 million overdoses in the US last year.
Harm reduction strategies β long controversial in American drug policy β have gained bipartisan acceptance in the face of the death toll. Fentanyl test strips, which allow users to check whether a drug supply is contaminated, are now legal in 47 states (up from 7 five years ago) and are demonstrably reducing deaths in communities where they are widely distributed.
Medications for opioid use disorder β buprenorphine and methadone β are also reaching more Americans. Telehealth prescribing of buprenorphine, which became possible via regulatory changes during COVID, has expanded access dramatically, particularly in rural areas that previously had no addiction treatment providers.
Despite the progress, the crisis remains catastrophic. Even with the 12% decline, more Americans died of opioid overdoses last year than died in the entire Vietnam War.
